DFFN
Diffusion Pharmaceuticals Inc
Halal Rating :
Last Price
$2.13
Last updated:
Market Cap
-
7D Change
4.41%
1 Year Change
-76.33%
Company Overview
Exchange
Next Earnings Date
Diffusion Pharmaceuticals Inc. is a clinical-stage biotechnology company developing novel therapies to enhance the body's ability to deliver oxygen to areas where it is needed most. The company's lead product candidate is Trans Sodium Crocetinate (TSC), which is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, potentially providing improved treatments for conditions such as hypoxia, stroke, and cancer.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $1.94m | $7.34m | - | - | 0.00% | 0.00% |
| June 30, 2024 | $3.29m | $6.28m | - | - | 0.00% | 0.00% |
| March 31, 2024 | $2.35m | $4.94m | - | - | 0.00% | 0.00% |
Company Impact
Help us evaluate Diffusion Pharmaceuticals Inc's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.